RT Journal Article
SR Electronic
T1 Serum Carcinoembryonic Antigen Levels Before the First Curative Hepatectomy for Metastatic Colorectal Cancer Is a Predictor of Recurrence
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5351
OP 5355
DO 10.21873/anticanres.12863
VO 38
IS 9
A1 KAWAHARA, HIDEJIRO
A1 YOSHIDA, SEIYA
A1 TOHYAMA, YOICHI
A1 YANAGISAWA, SATORU
A1 MISAWA, TAKEYUKI
A1 YANAGA, KATSUHIKO
YR 2018
UL http://ar.iiarjournals.org/content/38/9/5351.abstract
AB Background/Aim: The aim of this study was to evaluate the usefulness of serum carcinoembryonic antigen (CEA) levels before the first curative hepatectomy for metastatic colorectal cancer as a predictor of recurrence. Patients and Methods: Between 2003 and 2010, 66 patients (45 male and 21 female) who underwent a first curative hepatectomy for metastatic colorectal cancer in our hospital were evaluated retrospectively. The mean patient age was 65.2 years (range=31-80 years). A total of 28 patients had synchronous liver metastasis, and the other 38 patients developed metachronous liver metastasis. Results: The 5-year relapse-free survival rate after the first hepatectomy of the 16 patients with normal serum CEA level was 61.1%, whereas that of the 50 patients with abnormal serum CEA level was 34.3% (p<0.001). Among patients whose serum CEA levels were abnormal, the 5-year relapse-free survival rate after the first hepatectomy of the 34 patients with serum CEA levels less than 50 ng/ml was 48.1%, whereas that of the 16 patients with serum CEA level equal to or greater than 50 ng/ml was 6.3% (p<0.001). All eleven patients whose serum CEA levels were at least 100 ng/ml developed recurrence within one year after hepatectomy. Conclusion: Serum CEA levels before the first curative hepatectomy for metastatic colorectal cancer seem to be a predictor of recurrence.